Through machine learning algorithms, CDK8 was finally identified as a key biomarker, and inhibitors targeting CDK8 may be able to be promising therapeutic agents for COPD combined with AF by inhibiting NF-kB-induced immune inflammatory responses. This evidence concerns the gene NFKB1 and chronic obstructive pulmonary disease.